Liebman focuses on complex FDA regulatory, compliance and legal matters affecting global pharmaceutical, biotechnology and medical device manufacturers. He counsels clients on federal and state requirements and develops legal and regulatory strategies to help commercialize their products.
The placement was led by Josh Bilgrei, Managing Director at Whistler, who said that he is "humbled to make the match between Scott and Sheppard. I've known Scott for decades (we actually went to summer camp together), but since I've known him as an attorney, it's been apparent that he's not only an incredible practitioner, but also a great boss and mentor with a team who would follow him anywhere. When Scott told me he was ready to explore new opportunities, Sheppard Mullin blew us away with their overall firm and life sciences strategy. Shon Glusky, Guy Halgren, Jon Newby and Luca Salvi were all integral to making this deal happen, and it was a pleasure to work with them. I'm looking forward to seeing what Scott and his team accomplish at Sheppard."
To learn more about the move, read Sheppard Mullin's statement HERE.